JPMorgan Chase & Co. Purchases 113,061 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

JPMorgan Chase & Co. increased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 130.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 199,691 shares of the life sciences company’s stock after purchasing an additional 113,061 shares during the period. JPMorgan Chase & Co. owned 0.26% of Integra LifeSciences worth $4,529,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Principal Financial Group Inc. raised its holdings in Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock valued at $7,294,000 after acquiring an additional 63,266 shares during the period. Nordea Investment Management AB raised its stake in Integra LifeSciences by 4.1% during the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after purchasing an additional 5,032 shares during the period. Romano Brothers AND Company purchased a new position in Integra LifeSciences in the 4th quarter worth approximately $204,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new position in Integra LifeSciences in the 4th quarter worth approximately $204,000. Finally, Nisa Investment Advisors LLC grew its holdings in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IART shares. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $22.71.

Integra LifeSciences Price Performance

IART stock opened at $15.83 on Friday. Integra LifeSciences Holdings Co. has a 52 week low of $15.46 and a 52 week high of $32.66. The firm has a market capitalization of $1.22 billion, a P/E ratio of -175.87, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a fifty day simple moving average of $21.30 and a two-hundred day simple moving average of $22.25. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter last year, the business posted $0.89 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. Analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.